Elevated expression of the gene signature for YAP1/TAZ activity is associated with poor prognosis in patients with non-small-cell lung cancer (NSCLC) (89, 90), which is consistent with the results of LUAD in our study (Figure 3). This evidence concerns the gene YAP1 and non-small cell lung carcinoma.